Search company, investor...

Gensia Pharmaceuticals

Founded Year



Merger | Merged

About Gensia Pharmaceuticals

Gensia Pharmaceuticals is engaged in the development of drugs to treat cardiovascular diseases. Merged into Sicor; Sicor since acquired by Teva Pharmaceuticals

Headquarters Location

19 Hughes

Irvine, California, 92618,

United States

Missing: Gensia Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Gensia Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Gensia Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Gensia Pharmaceuticals founded?

    Gensia Pharmaceuticals was founded in 1986.

  • Where is Gensia Pharmaceuticals's headquarters?

    Gensia Pharmaceuticals's headquarters is located at 19 Hughes, Irvine.

  • What is Gensia Pharmaceuticals's latest funding round?

    Gensia Pharmaceuticals's latest funding round is Merger.

  • Who are the investors of Gensia Pharmaceuticals?

    Investors of Gensia Pharmaceuticals include SICOR and Domain Associates.

  • Who are Gensia Pharmaceuticals's competitors?

    Competitors of Gensia Pharmaceuticals include Bexion Pharmaceuticals, Acetylon Pharmaceuticals, Surface Logix, Virdante Pharmaceuticals, Prolexys Pharmaceuticals and 11 more.

Compare Gensia Pharmaceuticals to Competitors

NexGenix Pharmaceuticals Holdings

NexGenix Pharmaceuticals is developing drugs for cancer, neurodegenerative diseases, and neurofibromatosis.

Prolexys Pharmaceuticals

Prolexys Pharmaceuticals is a developer of cancer and cardiovascular small molecule drugs.

Nora Pharmaceuticals

Nora Pharmaceuticals, in stealth mode, is a developer of women's reproductive health drugs and devices.

New River Pharmaceuticals - Alumni

New River Pharmaceuticals is developing pharmaceuticals that are generational improvements of widely-prescribed drugs in large and growing markets.

BioSentinel Pharmaceuticals

BioSentinel Pharmaceuticals was founded to create detection systems, to develop high specificity and sensitivity portable, biosensor devices and to discover antagonists for bioterrorism by use of botulinum neurotoxins (BoNTs).

Inimex Pharmaceuticals

Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. nnAdditional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.